Free Newsletter
| Get the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Sign up for free today! |
J&J takes $440M charge on Natrecor
Here's a good estimate of how much it costs when a drug goes into free-fall: $440 million. That's how much Johnson & Johnson is writing off on Natrecor, a heart failure treatment that went into a downward spiral when medical researchers suggested that it might boost the risk of kidney problems and death.
And oh, what a drug it was supposed to be. In 2003, J&J paid $2.4 billion for the biotech company Scios to get its hands on Natrecor. The drug sold at a rate of about $400 million in 2004. Then, in 2005, the safety concerns arose, and sales have been declining ever since. The $440 million charge is expected to show up in J&J's fourth-quarter earnings report.
- see this article from The New York Times
Related Articles:
FDA warns J&J unit on heart drug marketing. Report
DCRI tapped for major new Natrecor study. Report
Slumping Natrecor sales spur layoffs at Scios. Report
J&J: Natrecor study failed to reveal two deaths. Report
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness


